Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial.

Auteurs

Yared RA, Chen CC, Vandorpe A, Arvanitakis M, Delhaye M, Viesca MFY, Huberty V, Blero D, Toussaint E, Hittelet A, Verset D, Margos W, Le Moine O, Njimi H, Liao WC, Devière J, Lemmers A

  • Date de publication

    February 2024

  • Type

    Article

  • Review

    Pancreatology

  • Researcher's name

    Vandorpe Astrid

  • Hôpital

    Hôpital Erasme

  • Service

    Pharmacotechnie

  • PMID

    38431445

  • DOI

    10.1016/j.pan.2024.02.009